natriuretic-peptide--brain and Muscle-Weakness

COPD affects up to one third of patients with chronic heart failure. The coexistence of COPD and chronic heart failure presents clinicians with diagnostic and therapeutic challenges. Measurement of B-type natriuretic peptide plasma levels facilitates the diagnosis of acute dyspnea in patients known to have both COPD and chronic heart failure. Patients with COPD or chronic heart failure have skeletal muscle abnormalities that limit functional capacity independently from primary organ failure. Exercise training reverses skeletal muscle abnormalities in patients with COPD or chronic heart failure and may be particularly indicated in patients with coexistent COPD and chronic heart failure.

Topics: Biomarkers; Exercise; Heart Failure; Humans; Muscle Weakness; Muscular Atrophy; Natriuretic Peptide, Brain; Pulmonary Disease, Chronic Obstructive; Treatment Outcome

Topics: Diagnostic Errors; Dyspnea; Emergency Treatment; Escherichia coli Infections; Heart Failure; Humans; Muscle Weakness; Natriuretic Peptide, Brain; Pseudomonas Infections; Shock, Septic